Eton Pharmaceuticals (ETON) Investor Presentation summary

Vision and strategy

• Aims to become a leading ultra-rare disease company focused on patient access and innovative therapies.

• Pursues rapid portfolio growth to deliver more treatments for underserved populations.

• Growth strategy centers on organic expansion, internal pipeline development, and strategic acquisitions.

Portfolio and pipeline

• Built one of the broadest ultra-rare disease portfolios, with 7 commercial products and 6 pipeline programs.

• Recent acquisitions include Increlex and Galzin, with new pipeline assets Amglidia, ET-700, and ET-800 added.

• Pipeline targets pediatric endocrinology and metabolic disorders, with late-stage programs like ET-400, ET-600, ET-700, ET-800, Amglidia, and Zeneo.

Commercial execution and market opportunity

• Achieved record product revenue and GAAP profitability, with 16 consecutive quarters of sequential revenue growth.

• Clear path to $100M+ near-term revenue, driven by Increlex, Galzin, and ET-400.

• Commercial strategy leverages concentrated prescriber bases, patient advocacy partnerships, and robust patient support programs.